Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: A review of the literature

M. Rajpurkar, M. Chitlur, Michael Recht, D. L. Cooper

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.

Original languageEnglish (US)
Pages (from-to)464-471
Number of pages8
JournalHaemophilia
Volume20
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Thrombasthenia
Factor VIIa
Hemorrhage
recombinant FVIIa
Platelet Transfusion
Platelet Glycoprotein GPIIb-IIIa Complex

Keywords

  • Bleeding
  • Glanzmann's thrombasthenia
  • rFVIIa

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)
  • Medicine(all)

Cite this

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia : A review of the literature. / Rajpurkar, M.; Chitlur, M.; Recht, Michael; Cooper, D. L.

In: Haemophilia, Vol. 20, No. 4, 2014, p. 464-471.

Research output: Contribution to journalArticle

@article{c9837250fd624a029ed15941befae0df,
title = "Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: A review of the literature",
abstract = "Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79{\%}). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92{\%} bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93{\%}) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69{\%}) of 36 bleeds and 27 (96{\%}) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.",
keywords = "Bleeding, Glanzmann's thrombasthenia, rFVIIa",
author = "M. Rajpurkar and M. Chitlur and Michael Recht and Cooper, {D. L.}",
year = "2014",
doi = "10.1111/hae.12473",
language = "English (US)",
volume = "20",
pages = "464--471",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia

T2 - A review of the literature

AU - Rajpurkar, M.

AU - Chitlur, M.

AU - Recht, Michael

AU - Cooper, D. L.

PY - 2014

Y1 - 2014

N2 - Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.

AB - Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.

KW - Bleeding

KW - Glanzmann's thrombasthenia

KW - rFVIIa

UR - http://www.scopus.com/inward/record.url?scp=84904666888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904666888&partnerID=8YFLogxK

U2 - 10.1111/hae.12473

DO - 10.1111/hae.12473

M3 - Article

C2 - 24948404

AN - SCOPUS:84904666888

VL - 20

SP - 464

EP - 471

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 4

ER -